Skip to content
MARKETS / NASDAQ / DCTH
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Delcath Systems, Inc. DCTH

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$85.2M
▲ 129.1% YoY
$2.7M
$21.0M
In brief

What this company does

Its lead product, the HEPZATO KIT (melphalan for Injection/Hepatic Delivery System), a drug/device combination product, was approved by the FDA on August 14, 2023, as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases. In Europe, the hepatic delivery system is a stand-alone medical device with the same components as HEPZATO but without the melphalan hydrochloride, approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. The company operates as one operating segment. As of February 13, 2026, including its management team, Delcath had approximately 156 full time employees, of which 141 are located in the United States and 15 are located in Europe.

Written from the business description in DELCATH SYSTEMS, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth
USD 85.2M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 85.2 · Net income 2.7
40M80M-20M-40M200920112013201520172019202120232025
Compound annual growth
+215.3%
+47.5%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
3 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 0.8% · Net 3.2%
-5000%-10000%-15000%200920112013201520172019202120232025
ROE
FY2025 · ROE 3.0%
-500%-1000%200920112013201520172019202120232025

Each USD of equity produced 3 cents of profit this year.

Cash & shareholders
USD 5.5M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 21.0
8M16M-20M-40M200920112013201520172019202120232025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks 5.5
2M4M-20M20092010201120242025

USD 5.5M in buybacks — 204% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 123.6M
EquityUSD 111.2M
CashUSD 43.5M
Current ratio10.92×

Equity funds 90% of total assets.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.10.00.00.00.0···0.00.00.00.00.00.00.00.0·
Operating income $B0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0
EBITDA $B0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.0···
Net income $B0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0
Free cash flow $B0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0
EPS, diluted $0.07−0.93−2.94−4.12−3.59−8.35−342.83−504.00−3250.00−3707.00−5096.00−1.84−5.10−13.54−0.68−1.20−0.82
Dividend / sh $·················
Payout %·················
ROE %3.0−62.4−961.4−1198.4−150.7−307.3···−505.4−110.0−72.1−121.0−225.0−111.9−176.7−129.9
Shares out B0.030.030.020.010.010.010.000.000.000.000.000.010.010.080.050.04·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 79 reconciliationsAUDITED

Reconciled in 18 of 19 fiscal years. 16 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2008

Share this section

Download image